BioScrip (BIOS) Posts Q2 GAAP Loss of $3.60/Share; Will Review Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
BioScrip Announces Steps To Enhance Shareholder Value
August 10, 2015 7:02 AM EDTELMSFORD, N.Y., Aug.10, 2015 /PRNewswire/ --Â BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company") today announced a multi-step plan to enhance shareholder value, improve financial flexibility and position BioScrip as a pure play infusion services company focused on high-growth services. The BioScrip Board of Directors has formed a committee that will be chaired by R. Carter Pate that is tasked with overseeing the implementation and execution of this plan.Â
BioScrip also announced today that, while the Company implements its financial improvement plan, the Board of Directors has authorized a... More
BioScrip Reports Second Quarter 2015 Financial Results
August 10, 2015 7:00 AM EDTELMSFORD, N.Y., Aug. 10, 2015 /PRNewswire/ -- BioScrip®, Inc. (NASDAQ: BIOS) (the "Company") today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.
Company Highlights During and Subsequent to the Second... More
